NCT03858686 - The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions

Asthma, COPD

Interventions

DRUG

FP-025 capsules

FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.

DRUG

Placebo FP-025 capsules

Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.

Trial Locations (2)

Academic Medical Centre/University of Amsterdam, Department of Respiratory Medicine and Experiment Immunology, Amsterdam

QPS Netherlands - Clinical Pharmacology Unit, Groningen